The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitor-naïve ALK-positive advanced NSCLC and in patients previously treated with crizotinib. A phase II trial showed that brigatinib is active in patients with ALK-positive metastatic NSCLC (mNSCLC) who had progressed on prior crizotinib (response rate 56 %, median PFS 16.7 months, median OS 34.1 months). We report final data from the UVEA-Brig study of brigatinib in ALK inhibitor-pretreated ALK-positive mNSCLC in clinical practice.
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
Novello, Silvia
2021-01-01
Abstract
The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitor-naïve ALK-positive advanced NSCLC and in patients previously treated with crizotinib. A phase II trial showed that brigatinib is active in patients with ALK-positive metastatic NSCLC (mNSCLC) who had progressed on prior crizotinib (response rate 56 %, median PFS 16.7 months, median OS 34.1 months). We report final data from the UVEA-Brig study of brigatinib in ALK inhibitor-pretreated ALK-positive mNSCLC in clinical practice.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer _ Elsevier Enhanced Reader.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
4.22 MB
Formato
Adobe PDF
|
4.22 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
